WO2023021259A1 - Composition for ketogenic diet and method for preparing same - Google Patents
Composition for ketogenic diet and method for preparing same Download PDFInfo
- Publication number
- WO2023021259A1 WO2023021259A1 PCT/FR2022/051583 FR2022051583W WO2023021259A1 WO 2023021259 A1 WO2023021259 A1 WO 2023021259A1 FR 2022051583 W FR2022051583 W FR 2022051583W WO 2023021259 A1 WO2023021259 A1 WO 2023021259A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- wax
- weight
- taurine
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 235000020887 ketogenic diet Nutrition 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 9
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229960003080 taurine Drugs 0.000 claims abstract description 28
- 150000002632 lipids Chemical class 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims abstract description 16
- -1 C12 fatty acid triglycerides Chemical class 0.000 claims abstract description 6
- 239000012530 fluid Substances 0.000 claims abstract description 5
- 229940057917 medium chain triglycerides Drugs 0.000 claims abstract description 5
- 238000002844 melting Methods 0.000 claims abstract description 5
- 230000008018 melting Effects 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract description 3
- 239000002562 thickening agent Substances 0.000 claims abstract description 3
- 239000001993 wax Substances 0.000 claims description 18
- 239000003240 coconut oil Substances 0.000 claims description 17
- 235000019864 coconut oil Nutrition 0.000 claims description 17
- 229920001202 Inulin Polymers 0.000 claims description 11
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 11
- 229940029339 inulin Drugs 0.000 claims description 11
- 239000010460 hemp oil Substances 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 235000013871 bee wax Nutrition 0.000 claims description 6
- 239000012166 beeswax Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 240000007185 Albizia julibrissin Species 0.000 claims description 2
- 235000011468 Albizia julibrissin Nutrition 0.000 claims description 2
- 244000298479 Cichorium intybus Species 0.000 claims description 2
- 244000020551 Helianthus annuus Species 0.000 claims description 2
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 2
- 235000013868 candelilla wax Nutrition 0.000 claims description 2
- 239000004204 candelilla wax Substances 0.000 claims description 2
- 229940073532 candelilla wax Drugs 0.000 claims description 2
- 235000013869 carnauba wax Nutrition 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 230000008719 thickening Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000723343 Cichorium Species 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000004140 ketosis Effects 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000020197 coconut milk Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Orally administrable composition for a ketogenic diet, comprising a mass proportion of lipids of between 70 and 92%, including 30 to 65% of medium-chain triglycerides, known as MCTs (C6 to C12 fatty acid triglycerides), and from 5 to 15% of taurine, preferably between 7 and 12% of taurine, and a thickener chosen from an edible wax with a melting point of between 55 and 85°C. The composition for a ketogenic diet is prepared according to the method comprising mixing said edible wax and the MCT triglycerides, with stirring, at a temperature at which the edible wax is liquid, adding taurine, then, after cooling, introducing the other ingredients, still with stirring, in order to obtain said composition capable of thickening while standing at ambient temperature and of returning to a fluid appearance with stirring, while at the same time preserving the homogeneity thereof.
Description
Description Description
Titre de l'invention : Composition pour régime cétogène et son procédé de préparation Title of the invention: Composition for ketogenic diet and process for its preparation
[0001] DOMAINE DE L’INVENTION [0001] FIELD OF THE INVENTION
[0002] La présente invention concerne le domaine des régimes cétogènes et plus particulièrement une composition pour régime cétogène et son procédé de préparation. The present invention relates to the field of ketogenic diets and more particularly to a composition for a ketogenic diet and its method of preparation.
[0003] Le régime cétogène consiste à favoriser, dans l’alimentation, une consommation très importante de lipides en réduisant considérablement la proportion des glucides, sans modifier l’apport en protéines. L’apport en lipides, principalement des acides gras, peut atteindre de 70 à 90 % de la ration calorique journalière, alors que les apports en hydrates de carbone peuvent être réduits jusqu’à 50 g par jour, voire à 20 g par jour. Les réserves de glucose dans l’organisme étant alors insuffisantes, le substrat énergétique principal est fourni par la dégradation des acides gras en corps cétoniques ; d’où le nom de phénomène de cétose. [0003] The ketogenic diet consists of promoting, in the diet, a very high consumption of lipids by considerably reducing the proportion of carbohydrates, without modifying the protein intake. Lipid intake, mainly fatty acids, can reach 70 to 90% of the daily calorie intake, while carbohydrate intake can be reduced to 50 g per day, or even 20 g per day. Since the glucose reserves in the body are then insufficient, the main energy substrate is provided by the degradation of fatty acids into ketone bodies; hence the name ketosis phenomenon.
[0004] ART ANTERIEUR [0004] PRIOR ART
[0005] Il est connu depuis de nombreuses années qu’un tel régime alimentaire cétogène pouvait avoir des effets anti-convulsants chez des épileptiques et faire disparaître des épilepsies sévères pharmaco résistantes, ou encore pouvait soulager des personnes souffrant d'effets secondaires graves dus à des traitements allopathiques. [0005] It has been known for many years that such a ketogenic diet could have anti-convulsant effects in epileptics and make severe drug-resistant epilepsies disappear, or even could relieve people suffering from serious side effects due to allopathic treatments.
[0006] Divers brevets ont proposé plus récemment des compositions alimentaires non seulement utiles pour le traitement de l’épilepsie, mais également en cas de diabète, tumeurs, déficience cognitive, autisme, obésité, lésions à la moelle épinière, maladie d’Alzheimer, ou de Parkinson. [0006] Various patents have more recently proposed food compositions not only useful for the treatment of epilepsy, but also in the event of diabetes, tumours, cognitive impairment, autism, obesity, spinal cord injuries, Alzheimer's disease, or Parkinson's.
[0007] Dans ce contexte, le document CN111280442A décrit un biscuit comprenant les proportions massiques suivantes : 44-78 parties de lipides, 10-21 parties de protéines, 4,5-45,5 parties de glucides et 3-19 parties de fibres alimentaires solubles dans l’eau, les lipides étant composés de 30-50 % d’acides gras à chaine moyenne et 50-70 % d’acides gras à longues chaines. Ces biscuits
renferment également de faibles proportions (inférieures à 0,4 parties massiques) de taurine, carnitine, DHA et vitamines. Cette préparation est solide et ne convient pas à certains types de patients, par exemple aux personnes susceptibles de faire des fausses routes. [0007] In this context, document CN111280442A describes a biscuit comprising the following mass proportions: 44-78 parts of lipids, 10-21 parts of proteins, 4.5-45.5 parts of carbohydrates and 3-19 parts of fibers water-soluble foods, lipids being composed of 30-50% medium-chain fatty acids and 50-70% long-chain fatty acids. These cookies also contain small proportions (less than 0.4 parts by mass) of taurine, carnitine, DHA and vitamins. This preparation is solid and is not suitable for certain types of patients, for example, people who are prone to slipping.
[0008] En parallèle, plusieurs études ont montré que la supplémentation en taurine protège contre les maladies associées aux défauts mitochondriaux, telles que les maladies mitochondriales, le syndrome métabolique, le cancer, les maladies cardiovasculaires et les troubles neurologiques (Jong et al, « The Role of Taurine in Mitochondria Health: More Than Just an Antioxidant ». Molecules. 2021 Aug 13;26(16):4913 ; Ohsawa Y. et Al., « Taurine supplementation for prevention of stroke-like episodes in MELAS: A multicentre, open-label, 52-week phase III trial ». J. Neurol. Neurosurg. Psychiatry. 2019;90:529-536). [0008] In parallel, several studies have shown that taurine supplementation protects against diseases associated with mitochondrial defects, such as mitochondrial diseases, metabolic syndrome, cancer, cardiovascular diseases and neurological disorders (Jong et al, “ The Role of Taurine in Mitochondria Health: More Than Just an Antioxidant". Molecules. 2021 Aug 13;26(16):4913; Ohsawa Y. et Al., "Taurine supplementation for prevention of stroke-like episodes in MELAS: A multicentre , open-label, 52-week phase III trial". J. Neurol. Neurosurg. Psychiatry. 2019;90:529-536).
[0009] On connaît également des compositions pour régime cétogène destinées au traitement de patients sous chimio- ou radio-thérapie : WO2012/113572 décrit une composition sous forme liquide, pour administration entérale, commercialisée sous la marque Ketocal® de la société Nutricia, comprenant des lipides, des protéines et des glucides dans un rapport pondéral lipides /glucides + protéines de 4/1 , les lipides renfermant au moins 25 % de triglycérides à chaine moyenne. Cette composition ne renferme pas de taurine. [0009] Compositions for ketogenic diet intended for the treatment of patients undergoing chemo- or radiotherapy are also known: lipids, proteins and carbohydrates in a lipid/carbohydrate+protein weight ratio of 4/1, the lipids containing at least 25% medium-chain triglycerides. This composition does not contain taurine.
[0010] Le document US2016/175378A1 divulgue une composition pour régime cétogène destinée à des patients gravement malades pour une administration entérale ou parentérale. Dans cette composition les lipides sont riches en omega-3 ou sont des triglycérides à chaine moyenne (en abrégé TCM). Cette composition nutritive comprend 50 % de lipides et 50 % de protéines, en fait sous la forme d’un mélange d’acides aminés essentiels et non essentiels. [0010] Document US2016/175378A1 discloses a composition for a ketogenic diet intended for seriously ill patients for enteral or parenteral administration. In this composition the lipids are rich in omega-3 or are medium chain triglycerides (abbreviated MCT). This nutritional composition includes 50% lipids and 50% proteins, in fact in the form of a mixture of essential and non-essential amino acids.
[0011] BUTS DE L’INVENTION [0011] AIMS OF THE INVENTION
[0012] Un premier but de la présente invention est de proposer une composition pour régime cétonique administrable par voie orale, pour tout type de patient, sans risque de fausse route, c’est à dire par exemple à l’aide d’une cuillère. A first object of the present invention is to provide a composition for a ketone diet that can be administered orally, for any type of patient, without risk of going the wrong way, that is to say for example using a spoon. .
[0013] Un autre but de l’invention est de proposer une composition pour régime cétonique administrable par voie orale, à l’aspect gustatif amélioré, notamment pouvant être administrée à des enfants.
[0014] Un autre but de l’invention est de proposer une composition pour régime cétonique facilement incorporable à des aliments lors de repas. Another object of the invention is to propose a composition for a ketone diet which can be administered orally, with an improved taste aspect, in particular which can be administered to children. Another object of the invention is to provide a composition for a ketone diet that can easily be incorporated into foods during meals.
[0015] Encore un but de l’invention est de proposer une composition pour régime cétonique administrable par voie orale, renfermant une teneur en taurine supérieure aux compositions de l’art antérieur, la composition restant stable et homogène dans le temps. Cette stabilité de la composition est nécessaire, tant pour entrer dans un processus de préparation industriel, que pour l’utilisateur final. Another object of the invention is to provide a composition for a ketone diet that can be administered orally, containing a higher taurine content than the compositions of the prior art, the composition remaining stable and homogeneous over time. This stability of the composition is necessary, both to enter an industrial preparation process, and for the end user.
[0016] DESCRIPTION DE L’INVENTION [0016] DESCRIPTION OF THE INVENTION
[0017] A cet effet la présente invention propose une composition pour régime cétogène, administrable par voie orale, comprenant une proportion massique en lipides comprise entre 70 et 92 % dont 30 à 65 % de triglycérides à chaine moyenne dénommés TCM (triglycérides d’acides gras en Ce à C12), et de 5 à 15 % de taurine, de préférence entre 7 et 12 % de taurine. [0017] To this end, the present invention provides a composition for a ketogenic diet, which can be administered orally, comprising a mass proportion of lipids of between 70 and 92%, including 30 to 65% of medium-chain triglycerides called TCM (acid triglycerides fat C to C12), and 5 to 15% taurine, preferably between 7 and 12% taurine.
[0018] La taurine présente des propriétés de neurotransmission (Md. Jakaria ét al., Redox Biology, 2019) et intervient dans des fonctions cardiaques et musculaires (Yan-Jun Xu et al. Exp Clin Cardio Vol13 N°2, 2008). Elle est aussi impliquée dans le mécanisme de digestion des lipides. La combinaison lipides et taurine dans une même composition est donc tout à fait intéressante. [0018] Taurine has neurotransmission properties (Md. Jakaria et al., Redox Biology, 2019) and is involved in cardiac and muscular functions (Yan-Jun Xu et al. Exp Clin Cardio Vol13 N°2, 2008). It is also involved in the mechanism of lipid digestion. The combination of lipids and taurine in the same composition is therefore quite interesting.
[0019] L’utilisation de triglycérides TCM a en outre permis de manière surprenante d’incorporer des taux de taurine jusqu’à là jamais atteintes dans une composition huileuse, en particulier pour une administration orale. [0019] The use of MCT triglycerides has also surprisingly made it possible to incorporate levels of taurine hitherto never achieved in an oily composition, in particular for oral administration.
[0020] De préférence, les triglycérides TCM comprennent des huiles de noix de coco, de préférence un mélange d'huile vierge et d'huile raffinée, dans des proportions de 40 à 50 % en poids de la composition. La présence de ces huiles de noix de coco sous deux formes différentes améliore notablement le goût de la composition. L’huile vierge de coco est riche en triglycérides d’acides gras essentiels, notamment des acides laurique, palmitique, myristique, caprylique et caprique. De plus elle renferme des vitamines E, A, B3, B5 et B6. [0020] Preferably, the MCT triglycerides comprise coconut oils, preferably a mixture of virgin oil and refined oil, in proportions of 40 to 50% by weight of the composition. The presence of these coconut oils in two different forms significantly improves the taste of the composition. Virgin coconut oil is rich in triglycerides of essential fatty acids, including lauric, palmitic, myristic, caprylic, and capric acids. In addition, it contains vitamins E, A, B3, B5 and B6.
[0021] La composition selon l’invention peut comprendre également de l'huile de graines de chanvre, de préférence dans des proportions de 20 à 25 % en poids de la composition. L’huile de chanvre est en effet riche en acides gras essentiels
oméga 3 et permet de lutter contre le stress et l’anxiété, et même de prévenir la dépression. Elle renferme également des acides gras omega 6 et de la vitamine E. The composition according to the invention may also comprise hemp seed oil, preferably in proportions of 20 to 25% by weight of the composition. Hemp oil is indeed rich in essential fatty acids omega 3 and helps fight stress and anxiety, and even prevent depression. It also contains omega 6 fatty acids and vitamin E.
[0022] De manière avantageuse, la composition selon l’invention comprend des oméga-3 sous forme de DHA, de préférence dans des proportions de 5 à 12 %, de préférence encore dans des proportions de 7 à 10 % en poids de ladite composition. Advantageously, the composition according to the invention comprises omega-3 in the form of DHA, preferably in proportions of 5 to 12%, more preferably in proportions of 7 to 10% by weight of said composition .
[0023] De manière avantageuse, la composition selon l’invention peut comprendre au moins un prébiotique, tel que l'inuline, de préférence l'inuline de chicorée. L’inuline de chicorée est une fibre alimentaire hydrosoluble, hypocalorique stimulant le développement des bactéries de la flore intestinale et régulant la glycémie. Advantageously, the composition according to the invention may comprise at least one prebiotic, such as inulin, preferably chicory inulin. Chicory inulin is a water-soluble, low-calorie dietary fiber that stimulates the development of bacteria in the intestinal flora and regulates blood sugar.
[0024] Afin de pouvoir obtenir une composition incorporant une teneur importante en taurine, molécule très peu soluble dans les lipides, la présente invention comprend un agent épaississant choisi parmi une cire alimentaire à point de fusion compris entre 55 et 85 °C. Ceci permet l’obtention d’une composition apte à s’épaissir au repos à température ambiante (20 à 25 °C) et à reprendre un aspect fluide sous agitation, tout en conservant son homogénéité. In order to be able to obtain a composition incorporating a high content of taurine, a molecule which is very poorly soluble in lipids, the present invention comprises a thickening agent chosen from an edible wax with a melting point of between 55 and 85°C. This makes it possible to obtain a composition capable of thickening on standing at room temperature (20 to 25° C.) and of taking on a fluid appearance when stirred, while retaining its homogeneity.
L’administration par voie orale en est facilitée, par exemple à la cuillère. Oral administration is facilitated, for example by spoon.
[0025] De manière avantageuse, ladite cire alimentaire est une cire naturelle, de préférence choisie parmi la cire d'abeille, la cire de candelilla, la cire de tournesol, la cire de carnauba, la cire de mimosa, ou un mélange de celles-ci. Advantageously, said edible wax is a natural wax, preferably chosen from beeswax, candelilla wax, sunflower wax, carnauba wax, mimosa wax, or a mixture of those -this.
[0026] Selon un mode de réalisation préféré de l’invention, la cire alimentaire est la cire d'abeille, présente de préférence dans des proportions de 1 à 5 %, de préférence encore de 2 à 4 % en poids de la composition. According to a preferred embodiment of the invention, the food wax is beeswax, preferably present in proportions of 1 to 5%, more preferably 2 to 4% by weight of the composition.
[0027] La composition selon l’invention peut comprendre également, de préférence à une teneur totale ne dépassant pas 2 % en poids de la composition, des vitamines telles que des vitamines E, D, et/ou la coenzyme Q 10. The composition according to the invention may also comprise, preferably at a total content not exceeding 2% by weight of the composition, vitamins such as vitamins E, D, and/or coenzyme Q 10.
[0028] La composition selon l’invention peut comprendre également, de préférence à une teneur totale ne dépassant pas 2 % en poids de la composition, des acides aminés, autres que la taurine, parmi lesquels la leucine et/ou l’arginine.
[0029] L’arginine présente des propriétés anti-oxydantes, aide à la cognition et stimule l’hormone de croissance. The composition according to the invention may also comprise, preferably in a total content not exceeding 2% by weight of the composition, amino acids, other than taurine, including leucine and/or arginine. [0029] Arginine has antioxidant properties, helps cognition and stimulates growth hormone.
[0030] La leucine est connue pour agir sur le système nerveux et les fonctions neurologiques. [0030] Leucine is known to act on the nervous system and neurological functions.
[0031] Une supplémentation en sélénium, sous forme par exemple de sélénite de sodium, peut être prévue dans ladite composition à une teneur comprise entre 0,2 et 0,5 % massique. En effet, le sélénium est un oligo-élément essentiel, notamment pour ses fonctions sur le plan cardiaque, qui est déficitaire chez les patients habituellement sous régime cétogène. A selenium supplementation, for example in the form of sodium selenite, may be provided in said composition at a content of between 0.2 and 0.5% by mass. Indeed, selenium is an essential trace element, in particular for its cardiac functions, which is deficient in patients usually on a ketogenic diet.
[0032] Selon un mode préféré de réalisation de l’invention la composition comprend les pourcentages en poids suivants : de l'huile de chanvre 20 à 25 %, de l'huile vierge de noix de coco 20 à 25 %, de l'huile de coco TCM de 20 à 25 %, de la DHA 5 à 10 %, de la taurine 5 à 15 %, de l'inuline 2 à 10 %, de la cire alimentaire, à point de fusion compris entre 55 et 85 °C, 1 à 5 %, éventuellement, à une teneur totale ne dépassant pas 2 % en poids de la composition, des vitamines et/ou la coenzyme Q 10, et éventuellement, à une teneur totale ne dépassant pas 2 % en poids de la composition, des acides aminés parmi lesquels la leucine et/ou l’arginine. According to a preferred embodiment of the invention, the composition comprises the following percentages by weight: hemp oil 20 to 25%, virgin coconut oil 20 to 25%, 20-25% MCT coconut oil, 5-10% DHA, 5-15% taurine, 2-10% inulin, edible wax, melting point 55-85° C, 1 to 5%, optionally, at a total content not exceeding 2% by weight of the composition, of vitamins and/or coenzyme Q 10, and optionally, at a total content not exceeding 2% by weight of the composition, amino acids including leucine and/or arginine.
[0033] La composition ci-dessus est équilibrée sur le plan lipidique : équilibrée en oméga 3/6/9, DHA et TCM, et à apport réduit de glucides (teneur en glucides inférieure ou égale à 1 %, de préférence inférieure ou égale à 0,5 % massique), qui va faciliter la production de corps cétoniques, donc l’état de cétose de l’organisme. Ces corps cétoniques sont la nouvelle source d'énergie nécessaire au fonctionnement des organes, du cerveau et du cœur... Ils vont aussi permettre d'améliorer l'absorption de la vitamine D, de la Coenzyme Q10 et de la taurine au niveau intestinal, favorisant un bon microbiote intestinal et la production de neurotransmetteurs. En effet, les corps cétoniques et les huiles TCM vont devenir des "transporteurs" via la veine porte et non via le système lymphatique : l'accès est plus direct, efficace et rapide au niveau neuronal. The above composition is balanced in terms of lipids: balanced in omega 3/6/9, DHA and MCT, and with a reduced intake of carbohydrates (carbohydrate content less than or equal to 1%, preferably less than or equal to at 0.5% by mass), which will facilitate the production of ketone bodies, and therefore the body's state of ketosis. These ketone bodies are the new source of energy necessary for the functioning of the organs, the brain and the heart... They will also help to improve the absorption of vitamin D, Coenzyme Q10 and taurine at the intestinal level. , promoting a good intestinal microbiota and the production of neurotransmitters. Indeed, ketone bodies and MCT oils will become "carriers" via the portal vein and not via the lymphatic system: access is more direct, efficient and rapid at the neuronal level.
[0034] La composition selon l’invention peut ainsi accompagner et maintenir le suivi d’un régime cétogène, notamment chez des patients souffrant d’épilepsie.
[0035] La présente invention concerne également un procédé de préparation de la composition pour régime cétogène décrite ci-dessus comprenant les étapes suivantes : The composition according to the invention can thus accompany and maintain the monitoring of a ketogenic diet, in particular in patients suffering from epilepsy. The present invention also relates to a method for preparing the composition for the ketogenic diet described above comprising the following steps:
- mélange sous agitation à une température à une température à laquelle la cire alimentaire est liquide, de ladite cire et de l'huile vierge de noix de coco, - mixing with stirring at a temperature at a temperature at which the edible wax is liquid, said wax and virgin coconut oil,
- ajout au dit mélange sous agitation l'huile de coco TCM, l'huile de chanvre et la taurine, à une température supérieure à 35 °C, - addition to said mixture with stirring of MCT coconut oil, hemp oil and taurine, at a temperature above 35°C,
- puis après refroidissement à la température de 20 à 25 °C, introduction toujours sous agitation de l’huile DHA, l'inuline, les éventuelles vitamines et/ou la coenzyme Q 10, et les éventuels acides aminés, et - then after cooling to a temperature of 20 to 25°C, introduction, still with stirring, of DHA oil, inulin, any vitamins and/or coenzyme Q 10, and any amino acids, and
- obtention d’une composition apte à s’épaissir au repos à température ambiante de 20 à 25 °C et à reprendre un aspect fluide sous agitation, tout en conservant son homogénéité. - obtaining a composition capable of thickening on standing at room temperature of 20 to 25 ° C and of regaining a fluid appearance under stirring, while retaining its homogeneity.
[0036] Le procédé de l’invention n’altère pas les propriétés intrinsèques des composants lipidiques d’intérêt pour la production de corps cétoniques. The method of the invention does not alter the intrinsic properties of the lipid components of interest for the production of ketone bodies.
[0037] Ainsi la composition selon la présente invention, obtenue par ce procédé est une suspension en milieu huileux, stable dans le temps, que ce soit après un séjour au froid (réfrigérateur) ou une exposition à la chaleur modérée (25-30 °C) (mélange avec un autre aliment par exemple). Thus the composition according to the present invention, obtained by this process is a suspension in an oily medium, stable over time, whether after a stay in the cold (refrigerator) or exposure to moderate heat (25-30 ° C) (mixed with another food for example).
[0038] EXEMPLE [0038] EXAMPLE
[0039] Un exemple, non limitatif, de réalisation d’une composition selon l’invention est présenté ci-après ; les quantités sont exprimées en % massique de la composition finale. A non-limiting example of making a composition according to the invention is presented below; the amounts are expressed as % by mass of the final composition.
Constituants lipidiques (Fabricants) : Lipid constituents (Manufacturers):
- huile de chanvre (EXINNOV) 24,0 % - hemp oil (EXINNOV) 24.0%
- huile vierge de noix de coco (AKEMIA BIO) 24,0 % - virgin coconut oil (AKEMIA BIO) 24.0%
- huile de noix de coco TCM (CAMBRIGE) 23,2 % - MCT coconut oil (CAMBRIGE) 23.2%
- DHA 550-Y (FERMENTALG) 10,0 % - DHA 550-Y (FERMENTALG) 10.0%
- Taurine 10,0 % - Taurine 10.0%
- Cire d’abeille (COOPER) 2,5 % - Beeswax (COOPER) 2.5%
Autres constituants : Other constituents:
- inuline de chicorée (GONMISOL) 5 %
- Coenzyme Q 10 1 % - chicory inulin (GONMISOL) 5% - Coenzyme Q 10 1%
- Vitamine E 0,3 % - Vitamin E 0.3%
Vitamine D3 0,01 % Vitamin D3 0.01%
La teneur en glucides de cette composition est de 0,5 % massique. The carbohydrate content of this composition is 0.5% by mass.
On peut aussi ajouter à cette composition : You can also add to this composition:
- sélénite de sodium 0,25 mg /100 g. - sodium selenite 0.25 mg / 100 g.
[0040] La dose minimale par prise recommandée est de 10 mL de cette composition, en complément d’une alimentation séparée apportant des protéines. Elle ne nécessite ni dilution ni préparation spéciale et est ainsi administrable directement, en particulier à la cuillère, ou incorporée dans des aliments (sur des légumes) ou une boisson (par exemple un lait de coco). The minimum recommended dose per intake is 10 mL of this composition, in addition to a separate diet providing proteins. It does not require any dilution or special preparation and can therefore be administered directly, in particular with a spoon, or incorporated into food (on vegetables) or a drink (for example coconut milk).
[0041] Une dose de 10 mL de cette composition correspond à 320 kcal. A dose of 10 mL of this composition corresponds to 320 kcal.
[0042] La composition comprend une diversité de nature des lipides. La présence des huiles de coco améliore l’aspect gustatif et la texture légèrement pâteuse de la composition permet une administration sous la langue, présentant l’avantage d’une absorption sub-linguale. [0042] The composition comprises a diversity of the nature of the lipids. The presence of coconut oils improves the taste aspect and the slightly pasty texture of the composition allows administration under the tongue, offering the advantage of sublingual absorption.
[0043] Le procédé de préparation de ladite composition comprend tout d’abord le mélange sous agitation, au bain marie à une température comprise entre 60 et 70 °C, de la cire d’abeille et de l'huile vierge de noix de coco, puis l’ajout au dit mélange sous agitation de l'huile de coco TCM, l'huile de chanvre et ensuite la taurine en poudre. Le mélange est maintenu sous agitation jusqu’à refroidissement à la température de 20 à 25 °C. Toujours sous agitation sont ensuite introduits successivement l’inuline, la coenzyme Q 10, l’huile DHA, puis les éventuelles vitamines, et les éventuels acides aminés. Le mélange final est maintenu sous agitation au moins 10 min, puis conditionné en flacon. The process for preparing said composition firstly comprises mixing, with stirring, in a water bath at a temperature of between 60 and 70° C., beeswax and virgin coconut oil. , then adding to said mixture, with stirring, MCT coconut oil, hemp oil and then powdered taurine. The mixture is kept under stirring until it cools to 20 to 25°C. Still under agitation, inulin, coenzyme Q 10, DHA oil, then any vitamins and any amino acids are then successively introduced. The final mixture is kept stirring for at least 10 min, then packaged in a bottle.
[0044] Il est noté que des essais précédents sans huile TCM n’ont pas permis d’obtenir des compositions avec des taux de taurines aussi importants. Il a ainsi pu être constaté que la présence des triglycérides TCM est essentielle à la réalisation de la composition. It is noted that previous tests without MCT oil did not make it possible to obtain compositions with such high levels of taurine. It was thus able to be observed that the presence of the TCM triglycerides is essential to the production of the composition.
[0045] La composition obtenue est une pâte semi-liquide, apte à s’épaissir au repos à température ambiante de 20 à 25 °C et à reprendre un aspect fluide sous agitation, tout en conservant son homogénéité. Le procédé selon l’invention
permet d’incorporer à ladite composition pour régime cétogène une quantité importante (10 % dans l’exemple ci-dessus) de taurine.
The composition obtained is a semi-liquid paste, capable of thickening on standing at room temperature of 20 to 25° C. and of resuming a fluid appearance with stirring, while retaining its homogeneity. The method according to the invention makes it possible to incorporate into said composition for the ketogenic diet a large quantity (10% in the example above) of taurine.
Claims
[Revendication 1] Composition pour régime cétogène, administrable par voie orale, comprenant une proportion massique en lipides comprise entre 70 et 92 % dont 30 à 65 % de triglycérides à chaine moyenne dénommés TCM (triglycérides d’acides gras en Ce à C12), et de 5 à 15 % de taurine, de préférence entre 7 et 12 % de taurine. [Claim 1] Composition for a ketogenic diet, which can be administered orally, comprising a mass proportion of lipids of between 70 and 92%, including 30 to 65% of medium-chain triglycerides called TCM (triglycerides of C 12 to C 12 fatty acids), and 5 to 15% taurine, preferably between 7 and 12% taurine.
[Revendication 2] Composition selon la revendication 1 caractérisée en ce que les triglycérides TCM comprennent des huiles de noix de coco, de préférence un mélange d'huile vierge et d'huile raffinée, dans des proportions de 40 à 50 % en poids de la composition. [Claim 2] Composition according to Claim 1, characterized in that the MCT triglycerides comprise coconut oils, preferably a mixture of virgin oil and refined oil, in proportions of 40 to 50% by weight of the composition.
[Revendication 3] Composition selon la revendication 1 ou 2 caractérisée en ce qu'elle comprend également de l'huile de graines de chanvre, de préférence dans des proportions de 20 à 25 % en poids de la composition.[Claim 3] Composition according to Claim 1 or 2, characterized in that it also comprises hemp seed oil, preferably in proportions of 20 to 25% by weight of the composition.
[Revendication 4] Composition selon l'une quelconque des revendications précédentes caractérisée en ce qu'elle comprend des oméga-3 sous forme de DHA, de préférence dans des proportions de 5 à 12 %, de préférence encore dans des proportions de 7 à 10 % en poids de la composition. [Claim 4] Composition according to any one of the preceding claims, characterized in that it comprises omega-3s in the form of DHA, preferably in proportions of 5 to 12%, more preferably in proportions of 7 to 10 % by weight of the composition.
[Revendication 5] Composition selon l'une quelconque des revendications précédentes caractérisée en ce qu'elle comprend au moins un prébiotique, tel que l'inuline, de préférence l'inuline de chicorée. [Claim 5] Composition according to any one of the preceding claims, characterized in that it comprises at least one prebiotic, such as inulin, preferably chicory inulin.
[Revendication 6] Composition selon l'une quelconque des revendications précédentes caractérisée en ce qu'elle comprend un agent épaississant choisi parmi une cire alimentaire à point de fusion compris entre 55 et 85 °C. [Claim 6] Composition according to any one of the preceding claims, characterized in that it comprises a thickening agent chosen from an edible wax with a melting point of between 55 and 85°C.
[Revendication 7] Composition selon la revendication 6 caractérisée en ce que la cire alimentaire est une cire naturelle, de préférence choisie parmi la cire d'abeille, la cire de candelilla, la cire de tournesol, la cire de carnauba, la cire de mimosa, ou un mélange de celles-ci. [Claim 7] Composition according to Claim 6, characterized in that the edible wax is a natural wax, preferably chosen from beeswax, candelilla wax, sunflower wax, carnauba wax, mimosa wax , or a mixture thereof.
[Revendication 8] Composition selon la revendication au 6 ou 7 caractérisée en ce que la cire alimentaire est la cire d'abeille, présente de préférence dans des proportions de 1 à 5 %, de préférence encore de 2 à 4 % en poids de la composition. [Claim 8] Composition according to Claim 6 or 7, characterized in that the edible wax is beeswax, preferably present in proportions of 1 to 5%, more preferably 2 to 4% by weight of the composition.
[Revendication 9] Composition selon l'une quelconque des revendications précédentes comprenant également, de préférence à une teneur totale ne
dépassant pas 2 % en poids de la composition, des vitamines telles que des vitamines E, D, et/ou la coenzyme Q 10. [Claim 9] Composition according to any one of the preceding claims also comprising, preferably at a total content not not exceeding 2% by weight of the composition, vitamins such as vitamins E, D, and / or coenzyme Q 10.
[Revendication 10] Composition selon l'une quelconque des revendications précédentes comprenant également, de préférence à une teneur totale ne dépassant pas 2 % en poids de la composition, des acides aminés, autres que la taurine, parmi lesquels la leucine et/ou l’arginine. [Claim 10] Composition according to any one of the preceding claims also comprising, preferably in a total content not exceeding 2% by weight of the composition, amino acids, other than taurine, including leucine and/or arginine.
[Revendication 11] Composition selon l’une quelconque des revendications précédentes caractérisée en ce qu'elle comprend les pourcentages en poids suivants : de l'huile de chanvre 20 à 25 %, de l'huile vierge de noix de coco 20 à 25 %, de l'huile de coco TCM de 20 à 25 %, de la DHA 5 à 10 %, de la taurine 5 à 15 %, de l'inuline 2 à 10 %, de la cire alimentaire, à point de fusion compris entre 55 et 85 °C, 1 à 5 %, éventuellement, à une teneur totale ne dépassant pas 2 % en poids de la composition, des vitamines et/ou la coenzyme Q 10, et éventuellement, à une teneur totale ne dépassant pas 2 % en poids de la composition, des acides aminés parmi lesquels la leucine et/ou l’arginine. [Claim 11] Composition according to any one of the preceding claims, characterized in that it comprises the following percentages by weight: hemp oil 20 to 25%, virgin coconut oil 20 to 25% , 20 to 25% MCT coconut oil, 5 to 10% DHA, 5 to 15% taurine, 2 to 10% inulin, edible wax, with a melting point between 55 and 85°C, 1 to 5%, optionally, at a total content not exceeding 2% by weight of the composition, of vitamins and/or coenzyme Q 10, and optionally, at a total content not exceeding 2% by weight of the composition, amino acids including leucine and/or arginine.
[Revendication 12] Procédé de préparation de la composition pour régime cétogène selon la revendication 11 comprenant les étapes suivantes : [Claim 12] Process for the preparation of the composition for ketogenic diet according to claim 11 comprising the following steps:
- mélange sous agitation, à une température à laquelle la cire alimentaire est liquide, de ladite cire et de l'huile vierge de noix de coco, - mixing with stirring, at a temperature at which the food wax is liquid, of said wax and virgin coconut oil,
- ajout au dit mélange sous agitation de l'huile de coco TCM, l'huile de chanvre et la taurine, à une température supérieure à 35 °C, - addition to said mixture with stirring of MCT coconut oil, hemp oil and taurine, at a temperature above 35°C,
- puis après refroidissement à la température de 20 à 25 °C, introduction toujours sous agitation de l’huile DHA, l'inuline, les éventuelles vitamines et/ou la coenzyme Q 10, et les éventuels acides aminés, - then after cooling to a temperature of 20 to 25°C, introduction, still stirring, of DHA oil, inulin, any vitamins and/or coenzyme Q 10, and any amino acids,
- obtention d’une composition apte à se solidifier au repos à température ambiante de 20 à 25 °C et à reprendre un aspect fluide sous agitation, tout en conservant son homogénéité.
- obtaining a composition capable of solidifying on standing at room temperature of 20 to 25 ° C and of resuming a fluid appearance under stirring, while retaining its homogeneity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR2108712 | 2021-08-16 | ||
FR2108712A FR3126097A1 (en) | 2021-08-16 | 2021-08-16 | Composition for ketogenic diet and process for its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023021259A1 true WO2023021259A1 (en) | 2023-02-23 |
Family
ID=80595417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2022/051583 WO2023021259A1 (en) | 2021-08-16 | 2022-08-16 | Composition for ketogenic diet and method for preparing same |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR3126097A1 (en) |
WO (1) | WO2023021259A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012113572A1 (en) | 2011-02-24 | 2012-08-30 | N.V. Nutricia | Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
US20160175378A1 (en) | 2013-09-04 | 2016-06-23 | Beth Israel Deaconess Medical Center | New ketogenic diet and its use in treating the critically ill |
CN111280442A (en) | 2020-03-10 | 2020-06-16 | 深圳市捷利康生物科技有限公司 | Improved ketogenic diet and method of making same |
-
2021
- 2021-08-16 FR FR2108712A patent/FR3126097A1/en active Pending
-
2022
- 2022-08-16 WO PCT/FR2022/051583 patent/WO2023021259A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012113572A1 (en) | 2011-02-24 | 2012-08-30 | N.V. Nutricia | Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
US20160175378A1 (en) | 2013-09-04 | 2016-06-23 | Beth Israel Deaconess Medical Center | New ketogenic diet and its use in treating the critically ill |
CN111280442A (en) | 2020-03-10 | 2020-06-16 | 深圳市捷利康生物科技有限公司 | Improved ketogenic diet and method of making same |
Non-Patent Citations (6)
Title |
---|
FONTANA BARBARA D ET AL: "Taurine Protects from Pentylenetetrazole-Induced Behavioral and Neurochemical Changes in Zebrafish", MOLECULAR NEUROBIOLOGY, SPRINGER US, NEW YORK, vol. 56, no. 1, 11 May 2018 (2018-05-11), pages 583 - 594, XP036679307, ISSN: 0893-7648, [retrieved on 20180511], DOI: 10.1007/S12035-018-1107-8 * |
JONG ET AL.: "The Rôle of Taurine in Mitochondria Health: More Than Just an Antioxidant", MOLECULES, vol. 26, no. 16, 13 August 2021 (2021-08-13), pages 4913 |
KENDLER ET AL: "Taurine: An overview of its role in preventive medicine", PREVENTIVE MEDICINE, ACADEMIC PRESS, XX, vol. 18, no. 1, 1 January 1989 (1989-01-01), pages 79 - 100, XP027277168, ISSN: 0091-7435, [retrieved on 19890101] * |
MD. JAKARIA ET AL., REDOX BIOLOGY, 2019 |
OHSAWA Y.: "Taurine supplementation for prévention of stroke-like episodes in MELAS: A multicentre, open-label, 52-week phase III trial", J. NEUROL. NEUROSURG. PSYCHIATRY., vol. 90, 2019, pages 529 - 536 |
YAN-JUN XU ET AL., EXP CLIN CARDIO, vol. 13, no. 2, 2008 |
Also Published As
Publication number | Publication date |
---|---|
FR3126097A1 (en) | 2023-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0504055B2 (en) | Compositions comprising glucides for use in diet and therapy, and their uses | |
EP3135119A1 (en) | Beverage composition for weight gain suppression | |
JPH1118725A (en) | Nutrient composition for diabetes patient | |
WO2011012568A1 (en) | Nutritional composition for lactating women | |
EP2739166B1 (en) | Functional and stable protein mixture for food compositions for persons in need of an improvement or the maintenance of their body condition | |
JP2012523839A (en) | High fiber nutrition emulsion | |
JP2012523840A (en) | High fiber nutrition emulsion for blood glucose control | |
EP2330922B1 (en) | Feed for milk-producing animals, method for the production thereof, use thereof and milk produced | |
EP1037539B1 (en) | Method for accelerating protein digestion rate and modified protein product | |
EP3397265B1 (en) | Protein-rich enteral nutritional composition containing a high proportion of caseinates | |
JP2012523841A (en) | High fiber nutrition emulsion with glycerin | |
WO2023021259A1 (en) | Composition for ketogenic diet and method for preparing same | |
US8889654B2 (en) | Food formulation comprising glycogen | |
JPWO2002094039A1 (en) | Foods for improving protein / energy undernutrition | |
FR2929514A1 (en) | COMPOSITIONS COMPRISING MYRISTIC ACID, FATTY ACIDS COMPRISING AN N-5CIS, N-7TRANS CONJUGATED DIENE OR A N-5CIS, N-7TRANS, N-9CIS CONJUGATED TRIENE AND USES THEREOF | |
US20200068939A1 (en) | Nutritional compositions to increase and sustain blood ketone levels | |
EP2719292B1 (en) | Medical nutrition product intended for being administered to obese persons recently operated in bariatric surgery | |
FR3081686A1 (en) | FOOD COMPOSITION COMPRISING PHYCOCYANIN | |
EP4120850B1 (en) | Long-life liquid nutritional composition with high protein content | |
FR2815824A1 (en) | Soluble nutritional fiber with low viscosity, high molecular weight and minimal texturing effect, useful as bifidogenic additive in human or animal diets | |
JP2003516946A (en) | Compositions for improving the proliferative response during gastrointestinal adaptation and use in short bowel syndrome | |
WO2023076569A1 (en) | Nutritional composition for renal support | |
FR3088175A1 (en) | FOOD COMPLEX AND FOOD COMPOSITION COMPRISING SAID COMPLEX FOR IMPROVING DIGESTION AND PROTEIN ASSIMILATION | |
FR2929515A1 (en) | Use of two different fatty acids having different carbon atoms, as medicine and to prepare food, pharmaceutical or nutraceutical composition to prevent/treat chronic low-grade systemic inflammation and treat subjects having e.g. obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22765937 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |